Dehydroascorbic acid as an anti-cancer agent
Abstract Three discoveries together point the way to a potential treatment for cancer. In 1982, Poydock and colleagues found that dehydroascorbic acid has the remarkable ability to eliminate the aggressive mouse tumours, L1210, P388, Krebs sarcoma, and Ehrlich carcinoma. In 1993, Jakubowski found th...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2008-05, Vol.263 (2), p.164-169 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 169 |
|---|---|
| container_issue | 2 |
| container_start_page | 164 |
| container_title | Cancer letters |
| container_volume | 263 |
| creator | Toohey, John I |
| description | Abstract Three discoveries together point the way to a potential treatment for cancer. In 1982, Poydock and colleagues found that dehydroascorbic acid has the remarkable ability to eliminate the aggressive mouse tumours, L1210, P388, Krebs sarcoma, and Ehrlich carcinoma. In 1993, Jakubowski found that cancer cells (but not normal cells) contain measurable quantities of homocysteine thiolactone. Recently, the author found that dehydroascorbic acid reacts with homocysteine thiolactone converting it to the toxic compound, 3-mercaptopropionaldehyde. Taken together, these findings suggest that rapidly-dividing tumour cells make unusually large amounts of homocysteine thiolactone and that administered dehydroascorbic acid enters the cells and converts the thiolactone to mercaptopropionaldehyde which kills the cancer cells. The effectiveness of dehydroascorbic acid might be further increased by combining it with methionine and/or methotrexate to increase the homocysteine concentration in cancer cells. |
| doi_str_mv | 10.1016/j.canlet.2008.02.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1505475735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0304383508000943</els_id><sourcerecordid>3242061151</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-ccd7b9c6bd707c939ffd5946d14f04bbe8f81e66faf15edf6ecd6a3e5aaf14153</originalsourceid><addsrcrecordid>eNqFUctKxDAUDaLo-PgDkQG3tt40aZNuBBmfMOBCXYc0udHUsdWkI8zfmzoDghshcCGcB-ccQo4p5BRodd7mRncLHPICQOZQ5ADFFplQKYpM1BK2yQQY8IxJVu6R_RhbACi5KHfJHpVMSBDFhJxd4evKhl5H04fGm6k23k51nOouvcFnycRgmOoX7IZDsuP0IuLR5h6Q55vrp9ldNn-4vZ9dzjPDORsyY6xoalM1VoAwNauds2XNK0u5A940KJ2kWFVOO1qidRUaW2mGpU4fnJbsgJyudT9C_7nEOKi2X4YuWSpa_mQQbETxNcqEPsaATn0E_67DSlFQY0WqVeuK1FiRgkKlihLtZCO-bN7R_pI2nSTAxRqAKeKXx6Ci8ZhasD6gGZTt_X8OfwXMwnfe6MUbrjD-ZlExEdTjONO4Esi0UM0Z-waaSY1h</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505475735</pqid></control><display><type>article</type><title>Dehydroascorbic acid as an anti-cancer agent</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Collection</source><creator>Toohey, John I</creator><creatorcontrib>Toohey, John I</creatorcontrib><description>Abstract Three discoveries together point the way to a potential treatment for cancer. In 1982, Poydock and colleagues found that dehydroascorbic acid has the remarkable ability to eliminate the aggressive mouse tumours, L1210, P388, Krebs sarcoma, and Ehrlich carcinoma. In 1993, Jakubowski found that cancer cells (but not normal cells) contain measurable quantities of homocysteine thiolactone. Recently, the author found that dehydroascorbic acid reacts with homocysteine thiolactone converting it to the toxic compound, 3-mercaptopropionaldehyde. Taken together, these findings suggest that rapidly-dividing tumour cells make unusually large amounts of homocysteine thiolactone and that administered dehydroascorbic acid enters the cells and converts the thiolactone to mercaptopropionaldehyde which kills the cancer cells. The effectiveness of dehydroascorbic acid might be further increased by combining it with methionine and/or methotrexate to increase the homocysteine concentration in cancer cells.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2008.02.002</identifier><identifier>PMID: 18378072</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Acids ; Animals ; Antineoplastic Agents - therapeutic use ; Ascorbic Acid - therapeutic use ; Cancer ; Cancer therapies ; Cancer treatment ; Dehydroascorbic acid ; Dehydroascorbic Acid - therapeutic use ; Hematology, Oncology and Palliative Medicine ; Homocysteine ; Homocysteine - analogs & derivatives ; Homocysteine - metabolism ; Homocysteine thiolactone ; Humans ; Mercaptopropionaldehyde ; Methionine - metabolism ; Methionine auxotrophy ; Mice ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Studies ; Tumors ; Vitamin C</subject><ispartof>Cancer letters, 2008-05, Vol.263 (2), p.164-169</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2008 Elsevier Ireland Ltd</rights><rights>Copyright Elsevier Limited May 18, 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-ccd7b9c6bd707c939ffd5946d14f04bbe8f81e66faf15edf6ecd6a3e5aaf14153</citedby><cites>FETCH-LOGICAL-c443t-ccd7b9c6bd707c939ffd5946d14f04bbe8f81e66faf15edf6ecd6a3e5aaf14153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383508000943$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18378072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toohey, John I</creatorcontrib><title>Dehydroascorbic acid as an anti-cancer agent</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Abstract Three discoveries together point the way to a potential treatment for cancer. In 1982, Poydock and colleagues found that dehydroascorbic acid has the remarkable ability to eliminate the aggressive mouse tumours, L1210, P388, Krebs sarcoma, and Ehrlich carcinoma. In 1993, Jakubowski found that cancer cells (but not normal cells) contain measurable quantities of homocysteine thiolactone. Recently, the author found that dehydroascorbic acid reacts with homocysteine thiolactone converting it to the toxic compound, 3-mercaptopropionaldehyde. Taken together, these findings suggest that rapidly-dividing tumour cells make unusually large amounts of homocysteine thiolactone and that administered dehydroascorbic acid enters the cells and converts the thiolactone to mercaptopropionaldehyde which kills the cancer cells. The effectiveness of dehydroascorbic acid might be further increased by combining it with methionine and/or methotrexate to increase the homocysteine concentration in cancer cells.</description><subject>Acids</subject><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Ascorbic Acid - therapeutic use</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cancer treatment</subject><subject>Dehydroascorbic acid</subject><subject>Dehydroascorbic Acid - therapeutic use</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Homocysteine</subject><subject>Homocysteine - analogs & derivatives</subject><subject>Homocysteine - metabolism</subject><subject>Homocysteine thiolactone</subject><subject>Humans</subject><subject>Mercaptopropionaldehyde</subject><subject>Methionine - metabolism</subject><subject>Methionine auxotrophy</subject><subject>Mice</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Studies</subject><subject>Tumors</subject><subject>Vitamin C</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUctKxDAUDaLo-PgDkQG3tt40aZNuBBmfMOBCXYc0udHUsdWkI8zfmzoDghshcCGcB-ccQo4p5BRodd7mRncLHPICQOZQ5ADFFplQKYpM1BK2yQQY8IxJVu6R_RhbACi5KHfJHpVMSBDFhJxd4evKhl5H04fGm6k23k51nOouvcFnycRgmOoX7IZDsuP0IuLR5h6Q55vrp9ldNn-4vZ9dzjPDORsyY6xoalM1VoAwNauds2XNK0u5A940KJ2kWFVOO1qidRUaW2mGpU4fnJbsgJyudT9C_7nEOKi2X4YuWSpa_mQQbETxNcqEPsaATn0E_67DSlFQY0WqVeuK1FiRgkKlihLtZCO-bN7R_pI2nSTAxRqAKeKXx6Ci8ZhasD6gGZTt_X8OfwXMwnfe6MUbrjD-ZlExEdTjONO4Esi0UM0Z-waaSY1h</recordid><startdate>20080518</startdate><enddate>20080518</enddate><creator>Toohey, John I</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20080518</creationdate><title>Dehydroascorbic acid as an anti-cancer agent</title><author>Toohey, John I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-ccd7b9c6bd707c939ffd5946d14f04bbe8f81e66faf15edf6ecd6a3e5aaf14153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acids</topic><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Ascorbic Acid - therapeutic use</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cancer treatment</topic><topic>Dehydroascorbic acid</topic><topic>Dehydroascorbic Acid - therapeutic use</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Homocysteine</topic><topic>Homocysteine - analogs & derivatives</topic><topic>Homocysteine - metabolism</topic><topic>Homocysteine thiolactone</topic><topic>Humans</topic><topic>Mercaptopropionaldehyde</topic><topic>Methionine - metabolism</topic><topic>Methionine auxotrophy</topic><topic>Mice</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Studies</topic><topic>Tumors</topic><topic>Vitamin C</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toohey, John I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toohey, John I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dehydroascorbic acid as an anti-cancer agent</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2008-05-18</date><risdate>2008</risdate><volume>263</volume><issue>2</issue><spage>164</spage><epage>169</epage><pages>164-169</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Abstract Three discoveries together point the way to a potential treatment for cancer. In 1982, Poydock and colleagues found that dehydroascorbic acid has the remarkable ability to eliminate the aggressive mouse tumours, L1210, P388, Krebs sarcoma, and Ehrlich carcinoma. In 1993, Jakubowski found that cancer cells (but not normal cells) contain measurable quantities of homocysteine thiolactone. Recently, the author found that dehydroascorbic acid reacts with homocysteine thiolactone converting it to the toxic compound, 3-mercaptopropionaldehyde. Taken together, these findings suggest that rapidly-dividing tumour cells make unusually large amounts of homocysteine thiolactone and that administered dehydroascorbic acid enters the cells and converts the thiolactone to mercaptopropionaldehyde which kills the cancer cells. The effectiveness of dehydroascorbic acid might be further increased by combining it with methionine and/or methotrexate to increase the homocysteine concentration in cancer cells.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>18378072</pmid><doi>10.1016/j.canlet.2008.02.002</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2008-05, Vol.263 (2), p.164-169 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_journals_1505475735 |
| source | MEDLINE; Elsevier ScienceDirect Journals Collection |
| subjects | Acids Animals Antineoplastic Agents - therapeutic use Ascorbic Acid - therapeutic use Cancer Cancer therapies Cancer treatment Dehydroascorbic acid Dehydroascorbic Acid - therapeutic use Hematology, Oncology and Palliative Medicine Homocysteine Homocysteine - analogs & derivatives Homocysteine - metabolism Homocysteine thiolactone Humans Mercaptopropionaldehyde Methionine - metabolism Methionine auxotrophy Mice Neoplasms - drug therapy Neoplasms - metabolism Studies Tumors Vitamin C |
| title | Dehydroascorbic acid as an anti-cancer agent |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T14%3A00%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dehydroascorbic%20acid%20as%20an%20anti-cancer%20agent&rft.jtitle=Cancer%20letters&rft.au=Toohey,%20John%20I&rft.date=2008-05-18&rft.volume=263&rft.issue=2&rft.spage=164&rft.epage=169&rft.pages=164-169&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2008.02.002&rft_dat=%3Cproquest_cross%3E3242061151%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505475735&rft_id=info:pmid/18378072&rft_els_id=1_s2_0_S0304383508000943&rfr_iscdi=true |